{
    "nct_id": "NCT05169567",
    "official_title": "postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy",
    "inclusion_criteria": "* Have a diagnosis of HR+, HER2- locally advanced or metastatic breast cancer\n* Have radiologic evidence of disease progression or recurrence either\n\n  * On treatment with a CDK4/6 inhibitor with aromatase inhibitor (AI) as initial therapy for advanced disease, or\n  * On/after treatment with a CDK4/6 inhibitor plus endocrine therapy (ET) administered as adjuvant therapy for early stage breast cancer\n* Must be deemed appropriate for treatment with ET\n* If female, have a postmenopausal status by natural or surgical means or by ovarian function suppression\n* Have Response Evaluable Criteria in Solid Tumors (RECIST) evaluable disease (measurable disease and/or nonmeasurable disease)\n* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale (Oken et al. 1982)\n* Have adequate renal, hematologic, and hepatic organ function\n* Must be able to swallow capsules/tablets\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis\n* Have symptomatic or untreated central nervous system metastasis\n* Have received any systemic therapy between disease recurrence/progression and study screening\n* Have received more than 1 line of therapy for advanced or metastatic disease.\n* Have received prior chemotherapy for metastatic breast cancer (MBC)\n* Have received prior treatment with fulvestrant, any investigational estrogen receptor (ER)-directed therapy (including selective ER degraders [SERDs] and non-SERDs), any phosphatidylinositol 3-kinase (PI3K)-, mammalian target of rapamycin (mTOR)-, or protein kinase B (AKT)-inhibitor",
    "miscellaneous_criteria": ""
}